Amisulpride measured by LC-MS/MS
Clinical details: 
Amisulpride (aminosultopride) is an atypical antipsychotic drug that has been in clinical use since 1992. It is supplied as the free base in 50, 100, 200 and 400 mg tablets or capsules for oral administration, as well as a 50 mg/mL solution for parenteral injection. It is readily absorbed following oral administration and is largely excreted unchanged. Its plasma half-life is ca. 12 h. Adverse reactions include somnolence, hypotension, dystonia, akathisia and extrapyramidal effects. Oral maintenance doses for adults range from 50–400 mg/d. Amisulpride assay is useful in assessing adherence and in the diagnosis of acute poisoning. A target plasma concentration range of 100–400 µg/L during effective therapy has been suggested.
Reference range: 


Sample type and Volume required: 
4 mL of ETDA whole blood is preferred (pre-dose or ‘trough’ sample). Serum or plasma can be used if required, but please avoid gel-separator tubes.
Turnaround time: 
5 working days
Storage and transport: 
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Toxicology Department at King's Hospital
020 3299 5881
King's College Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 03/10/2022